{"id":742044,"date":"2010-11-11T08:30:00","date_gmt":"2010-11-11T08:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/"},"modified":"2026-08-10T13:01:14","modified_gmt":"2026-08-10T17:01:14","slug":"merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/","title":{"rendered":"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness"},"content":{"rendered":"<p class=\"bwalignc\">       Public Health Officials Confirm Significant Progress Toward the Goal        of Elimination of River Blindness in Latin America by 2012     <\/p>\n<p>WHITEHOUSE STATION, N.J.&#8211;(BUSINESS WIRE)&#8211;Public health officials at the 20<sup>th<\/sup> Inter-American Conference        on Onchocerciasis in Antigua, Guatemala, confirmed that more than        one-third of all Latin Americans who ran the risk of contracting river        blindness (onchocerciasis), a leading cause of preventable blindness,        are no longer at risk.     <\/p>\n<p>       Officials attribute the successes in Latin America to a sustained        public-private partnership led by the Carter Center that offers drug        treatment and health education. The Carter Center \u2013 through its        sponsorship of the Onchocerciasis Elimination Program of the Americas        (OEPA) \u2013 assists national ministries of health in six affected countries        in Latin America to conduct health education and distribute Merck&#8217;s        medicine, ivermectin (registered trademark MECTIZAN).     <\/p>\n<p>       &#8220;Our continued progress toward eliminating river blindness is bringing        improved health to hundreds of thousands of people in the Americas and        the preservation of vision for future generations,&#8221; said former U.S.        President Jimmy Carter. &#8220;With continued focus, we can ensure that river        blindness will no longer be a threat to people in the Western        Hemisphere.&#8221;     <\/p>\n<p>       &#8220;Merck has donated MECTIZAN for more than 20 years and will continue to        do so until river blindness becomes a disease of the past,&#8221; said Richard        T. Clark, chairman and CEO of Merck. &#8220;We are inspired by the progress in        Latin America and continue to believe that public-private partnerships        like this one are critical to achieving real improvements in global        health.&#8221;     <\/p>\n<p>       In addition Merck&#8217;s MECTIZAN Donation Program announced today it will        donate $150,000 to The Carter Center for post-treatment surveillance in        those areas where the transmission of river blindness has been        interrupted to confirm treatment with MECTIZAN is no longer necessary.        The World Health Organization requires three years of surveillance        before certifying that a country has officially eliminated river        blindness. The funding will be in the form of a &#8220;challenge grant&#8221;        whereby The Carter Center will raise an additional $150,000 in matching        funds, effectively mobilizing $300,000 for the effort.     <\/p>\n<p>       The Pan American Health Organization (PAHO) passed a historic resolution        in 2008, calling for transmission of river blindness in Latin America to        be stopped by 2012 and elimination certification by 2015. In Latin        America, river blindness historically affected people in Brazil,        Colombia, Ecuador, Guatemala, Mexico and Venezuela. Today, approximately        184,310 or 34 percent, of the 542,945 people previously at risk are no        longer threatened by river blindness.     <\/p>\n<p>       Colombia and Ecuador already have reduced onchocerciasis infection rates        low enough to effectively break the cycle of disease transmission        country-wide. Other countries are making progress. According to Dr.        Arturo Sanchez, director of the Vectorborne Diseases Program of the        Guatemalan Ministry of Health, &#8220;Guatemala expects to interrupt        onchocerciasis transmission in the last of its four affected areas very        soon, thereby becoming one of the next countries in the region to        achieve interruption of transmission.\u201d     <\/p>\n<p>       <b>The MECTIZAN Donation Program<\/b>     <\/p>\n<p>       In October 1987, Merck announced it would donate MECTIZAN \u2013 the only        well-tolerated drug known to halt the development of onchocerciasis \u2013 to        all who need it for as long as necessary until onchocerciasis is        eliminated as a public health problem. The MECTIZAN Donation Program        reaches more than 100 million people annually.     <\/p>\n<p>       In Latin America, since 1989, more than 9.6 million treatments with        donated MECTIZAN have been delivered by community health workers and        non-governmental organizations. Treatment programs currently exist in        Brazil, Guatemala, Mexico and Venezuela. Colombia and Ecuador are        undergoing post-treatment surveillance to confirm that transmission of        river blindness has been halted.     <\/p>\n<p>       <b>About The Carter Center Sponsored-OEPA<\/b>     <\/p>\n<p>       The Carter Center \u2013 through its sponsorship of Onchocerciasis        Elimination Program of the Americas (OEPA) \u2013 is leading a coalition of        partners&nbsp;in a historic effort to eliminate river blindness        (onchocerciasis) from the Western Hemisphere by 2015 (inclusive of the        three year required surveillance period). To wipe the debilitating        disease from the few remaining pockets, the Center&#8217;s OEPA assists the        ministries of health in the six affected countries and partners with        Merck, the Merck MECTIZAN Donation Program, PAHO, the U.S. Centers for        Disease Control and Prevention, Lions Clubs International Foundation,        the Bill &amp; Melinda Gates Foundation as well as academic institutions and        other organizations. The Carter Center was founded in 1982 by former        U.S. President Jimmy Carter and his wife, Rosalynn, in partnership with        Emory University, to advance peace and health worldwide. For more        information visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.oepa.net&amp;esheet=6507819&amp;lan=en-US&amp;anchor=www.oepa.net&amp;index=1&amp;md5=5ff2baa7d4157d101d47e5b5bcd546b7\">www.oepa.net<\/a>        or <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.cartercenter.org&amp;esheet=6507819&amp;lan=en-US&amp;anchor=www.cartercenter.org&amp;index=2&amp;md5=b3029696f4deac59d76acfce1a7d7b27\">www.cartercenter.org<\/a>     <\/p>\n<p>       <b>About Merck<\/b>     <\/p>\n<p>       Today&#8217;s Merck is a global healthcare leader working to help the world be        well. Merck is known as MSD outside the United States and Canada.        Through our prescription medicines, vaccines, biologic therapies, and        consumer care and animal health products, we work with customers and        operate in more than 140 countries to deliver innovative health        solutions. We also demonstrate our commitment to increasing access to        healthcare through far-reaching policies, programs and partnerships. For        more information, visit <a target=\"_blank\" href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.merck.com&amp;esheet=6507819&amp;lan=en-US&amp;anchor=www.merck.com&amp;index=3&amp;md5=550a7f56d536154c48ac6ce40b71cc46\">www.merck.com<\/a>.     <\/p>\n<\/p>\n<p><p>       Merck<br \/>Media:<br \/>Ron Rogers, 908-423-6449<br \/>or<br \/>Emily        Vlasak, 908-423-5231     <\/p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Public health officials at the 20 th Inter-American Conference on Onchocerciasis in Antigua, Guatemala, confirmed that more than one-third of all Latin Americans who ran the risk of contracting river blindness (onchocerciasis), a leading cause of preventable blindness, are no longer at risk. Officials attribute the successes in Latin America to a sustained public-private partnership led by the Carter Center that offers drug treatment and health education. The Carter Center \u2013 through its sponsorship of the Onchocerciasis Elimination Program of the Americas (OEPA) \u2013 assists national ministries of health in six affected countries in Latin America to conduct health education and distribute Merck&#8217;s medicine, ivermectin (registered trademark MECTIZAN). &#8220;Our continued progress toward eliminating river blindness is bringing improved health to hundreds of thousands of people in the Americas and the preservation of vision for future generations,&#8221; said former U.S. President Jimmy Carter. &#8220;With<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[54,289],"class_list":["post-742044","news_item","type-news_item","status-publish","hentry","tag-corporate-responsibility-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck and Partners Make Progress in Long-Term Commitment to End River Blindness - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Public health officials at the 20 th Inter-American Conference on Onchocerciasis in Antigua, Guatemala, confirmed that more than one-third of all Latin Americans who ran the risk of contracting river blindness (onchocerciasis), a leading cause of preventable blindness, are no longer at risk. Officials attribute the successes in Latin America to a sustained public-private partnership led by the Carter Center that offers drug treatment and health education. The Carter Center \u2013 through its sponsorship of the Onchocerciasis Elimination Program of the Americas (OEPA) \u2013 assists national ministries of health in six affected countries in Latin America to conduct health education and distribute Merck&#039;s medicine, ivermectin (registered trademark MECTIZAN). &quot;Our continued progress toward eliminating river blindness is bringing improved health to hundreds of thousands of people in the Americas and the preservation of vision for future generations,&quot; said former U.S. President Jimmy Carter. &quot;With\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-10T17:01:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\\\/\",\"name\":\"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2010-11-11T08:30:00+00:00\",\"dateModified\":\"2026-08-10T17:01:14+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/","og_locale":"en_US","og_type":"article","og_title":"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness - Merck.com","og_description":"Public health officials at the 20 th Inter-American Conference on Onchocerciasis in Antigua, Guatemala, confirmed that more than one-third of all Latin Americans who ran the risk of contracting river blindness (onchocerciasis), a leading cause of preventable blindness, are no longer at risk. Officials attribute the successes in Latin America to a sustained public-private partnership led by the Carter Center that offers drug treatment and health education. The Carter Center \u2013 through its sponsorship of the Onchocerciasis Elimination Program of the Americas (OEPA) \u2013 assists national ministries of health in six affected countries in Latin America to conduct health education and distribute Merck's medicine, ivermectin (registered trademark MECTIZAN). \"Our continued progress toward eliminating river blindness is bringing improved health to hundreds of thousands of people in the Americas and the preservation of vision for future generations,\" said former U.S. President Jimmy Carter. \"With","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/","og_site_name":"Merck.com","article_modified_time":"2026-08-10T17:01:14+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/","name":"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2010-11-11T08:30:00+00:00","dateModified":"2026-08-10T17:01:14+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-and-partners-make-progress-in-long-term-commitment-to-end-river-blindness\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck and Partners Make Progress in Long-Term Commitment to End River Blindness"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"b2ae467a-a679-474f-94ca-03e7822dbeb2","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Merck-and-Partners-Make-Progress-in-Long-Term-Commitment-to-End-River-Blindness-2010.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742044","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742044\/revisions"}],"predecessor-version":[{"id":3679182,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/742044\/revisions\/3679182"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=742044"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=742044"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}